Table 2.
Univariate analysis of prognostic factors
| Variable | Cases | Events | Mean survival (months) | HR a (95% CI b ) | p |
|---|---|---|---|---|---|
| Gender | 0.504 | ||||
| Male | 61 | 47 | 16.176 | 1 | |
| Female | 47 | 37 | 19.699 | 0.862 (0.559-1.331) | |
| Age (y) | 0.176 | ||||
| < 60 | 47 | 35 | 21.381 | 1 | |
| ≥ 60 | 61 | 49 | 15.254 | 1.352 (0.874-2.092) | |
| Location of tumor | 0.026* | ||||
| Head | 72 | 52 | 20.770 | 1 | |
| Body and tail | 36 | 32 | 12.235 | 1.655 (1.062-2.579) | |
| Size of tumor (cm) | 0.358 | ||||
| ≤ 2 | 22 | 67 | 20.116 | 1 | |
| >2 | 86 | 17 | 17.290 | 1.285 (0.753-2.192) | |
| Differentiation | <0.001* | ||||
| Well | 15 | 8 | 34.953 | 1 | |
| Moderate | 83 | 66 | 15.803 | 2.532 (1.202-5.332) | 0.015* |
| Poor | 10 | 10 | 5.700 | 7.624 (2.918-19.916) | <0.001* |
| Nerve infiltration | 0.699 | ||||
| No | 38 | 29 | 21.137 | 1 | |
| Yes | 70 | 55 | 16.406 | 1.094 (0.694-1.725) | |
| TNM staging | 0.007* | ||||
| IA + IB | 15 | 12 | 24.448 | 1 | |
| IIA | 33 | 25 | 17.483 | 1.371 (0.684-2.751) | 0.374 |
| IIB | 46 | 34 | 18.785 | 1.507 (0.777-2.925) | 0.225 |
| III + IV | 14 | 13 | 6.982 | 3.729 (1.664-8.358)) | 0.001* |
| Serum CA19-9 (kU/L) | 0.014* | ||||
| ≤ 39 | 31 | 16 | 28.993 | 1 | |
| > 39 | 77 | 68 | 14.556 | 1.988 (1.150-3.436) | |
| Serum CA50 (kU/L) | 0.065* | ||||
| ≤ 25 | 49 | 30 | 24.091 | 1 | |
| > 25 | 59 | 54 | 14.459 | 1.529 (0.975-2.398) | |
| Serum CEA (μg/L) | 0.032* | ||||
| ≤ 5 | 64 | 44 | 22.116 | 1 | |
| > 5 | 44 | 40 | 12.072 | 1.609 (1.041-2.488) | |
| MUC4 (2-ΔCt) | <0.001* | ||||
| Low (<0.056) | 75 | 54 | 22.101 | 1 | |
| High (≥0.056) | 33 | 30 | 8.054 | 2.595 (1.612-4.179) | |
| MUC4/Y (2-ΔCt) | 0.003* | ||||
| Low (<0.0044) | 79 | 58 | 21.126 | 1 | |
| High (≥0.0044) | 29 | 26 | 8.835 | 2.077 (1.283-3.365) |
aHR, hazard ratio; bCI, confidence interval; * P ≤ 0.10.